Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.
about
The dopamine hypothesis of schizophrenia: version III--the final common pathwayBrain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter SystemsOn the selection of mice for haloperidol response and non-responseGenetics of schizophrenia: from animal models to clinical studiesBrain imaging research: does the science serve clinical practice?The role of imaging in proof of concept for CNS drug discovery and development.Structural and functional brain imaging in schizophrenia.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part IIT102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variabilityDetermining the optimal dose of haloperidol in first-episode psychosis.The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome.Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cuesStriatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjectsPET and SPECT imaging in psychiatric disorders.What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas.Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.Factors associated with response to clozapine in schizophrenia: a review.How have developments in molecular imaging techniques furthered schizophrenia research?Serotonin 2A receptor antagonists for treatment of schizophrenia.Positron emission tomography in psychiatric disorders.Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.Traditional receptor theory and its application to neuroreceptor measurements in functional imaging.New perspectives on the clinical neurobiology of treatment response in schizophrenia.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine.Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia.White matter changes in treatment refractory schizophrenia: Does cognitive control and myelination matter?In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity.The neuropsychology of schizophrenia: A perspective from neurobehavioral geneticsAntipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) studyWhy don't preschizophrenic children have delusions and hallucinations?Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics
P2860
Q22242827-162EC19C-5CED-40F9-8658-CDD8A8D258A0Q26786247-6F899510-A251-4008-AFEB-1F9CCDD4317AQ28326447-26F58A8D-A723-4069-BB25-633CB8F46B2DQ30532039-58BEDA96-8D1F-4897-8069-80BCC312AD8CQ31131085-05669B0B-335F-4DF5-A820-15C4554713B9Q33374793-E96B9806-24D2-464C-9248-D8A95917C4C8Q33396727-B4D9415C-A02E-4BC6-A3F6-68B062B51FA4Q33612521-FFB224BA-B560-4888-8714-7E37E91CF863Q33922225-8DFBBB12-03D0-4AE1-9C82-0DD508742407Q34107268-0B46631C-1D2E-43B5-828C-B95A770BE953Q34678995-948E8F04-ED52-4049-8741-E3EF0E4FB829Q34820251-724BF28E-BCB1-4173-8285-FAD0B07444F7Q35950793-80013B24-55D0-44F5-B522-5027CAF01972Q36249164-58F2CC5D-ABDD-4D61-B7F0-F9E518FB2348Q36371727-AFA607A5-FF9E-48CE-82F0-667B8F9A3EBAQ36728072-9D80CA52-C13D-48C9-94BD-7A8FABC3FE3CQ36811276-0BA3EA71-5604-4995-8331-6583F0263274Q36820162-9566ADE3-1CE4-4C01-9031-59804ADE90CFQ36941951-F867E3E3-E739-488A-B972-AB65483E2287Q37300007-A16D57F9-D8FC-4767-BEBF-BD3505CC0505Q37829639-DE0FE416-55DB-4395-8362-C15AAFA47D4CQ37899193-56A3FF00-707A-43AF-8275-0A2F507D7962Q37975237-516E00D5-DE58-44D0-AC81-F117BEFF1591Q38219577-9093028D-20FF-4735-BF9C-15B324E7C162Q40382126-A746BA22-F126-4403-8D31-336936D9B8ABQ40623093-50F6B97A-8313-45C1-9A5D-5509ED8E1037Q41846717-97B7BF25-7825-4836-8DA1-FF97BBFD3689Q42939853-57676D68-B83C-4138-8BC4-5FD8D85E9E36Q44374816-109D9850-2EB1-4930-831E-02754A7986B0Q44808044-45D649B8-84CA-40EE-8B59-ACC5D5D44DB5Q46674415-193C26E3-0C43-4882-ADEC-CB1004FB813BQ47120840-D9BA53D9-542B-44B2-B955-66811538B05EQ47693465-5E1BBF51-1028-46AC-89AC-D53621AB7F55Q49068786-63D3AEF9-3709-4B63-BCD4-B4BDF50A790AQ49736198-00D56DC5-9F10-46D8-AD2A-BC0D8C20ED82Q56896418-9D8056A0-0EBF-4A26-B9CD-1D818D6EC45BQ57403516-8C7921C3-0FE0-49AE-AA35-07958F8BC795Q57403541-37319BB0-B3CB-4EF2-99C4-3E4E9CC00A3EQ58698014-19696EC1-5765-4F84-ACC4-E8EBE65CAB36
P2860
Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Dopamine blockade and clinical ...... al subgroups of schizophrenia.
@en
Dopamine blockade and clinical ...... al subgroups of schizophrenia.
@nl
type
label
Dopamine blockade and clinical ...... al subgroups of schizophrenia.
@en
Dopamine blockade and clinical ...... al subgroups of schizophrenia.
@nl
prefLabel
Dopamine blockade and clinical ...... al subgroups of schizophrenia.
@en
Dopamine blockade and clinical ...... al subgroups of schizophrenia.
@nl
P2093
P356
P1476
Dopamine blockade and clinical ...... al subgroups of schizophrenia.
@en
P2093
Barouche F
Rotrosen J
P304
P356
10.1176/AJP.146.7.905
P407
P577
1989-07-01T00:00:00Z